Division of Rheumatology, George Washington University, Washington, District of Columbia, USA.
Ann N Y Acad Sci. 2011 Jun;1228:167-74. doi: 10.1111/j.1749-6632.2011.06082.x.
The role of fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the diagnosis, staging, and monitoring of neoplastic conditions is well established. The clinical utility of PET/CT has now expanded to the diagnosis of autoimmune, inflammatory, infectious, as well as non-neoplastic conditions, such as the vasculitides, atherosclerosis, and granulomatous conditions, including sarcoidosis and inflammatory bowel disease, in addition to a variety of neurologic disorders. The availability of new PET radiotracers is expected to expand PET/CT applications to a variety of other clinical domains. New radioligands for studying inflammation and neurodegenerative processes are under development. Here, we discuss the evolving potential role of PET imaging for the evaluation and monitoring of miscellaneous conditions, including osteoarthritis, interstitial lung disease, vascular thromboses, and osteoporosis.
氟代-2-脱氧葡萄糖(FDG)正电子发射断层扫描(PET)在肿瘤疾病的诊断、分期和监测中的作用已得到充分证实。PET/CT 的临床应用现已扩展到自身免疫、炎症、感染以及非肿瘤性疾病的诊断,如血管炎、动脉粥样硬化和肉芽肿性疾病,包括结节病和炎症性肠病,以及各种神经退行性疾病。预计新的 PET 放射性示踪剂的出现将使 PET/CT 在各种其他临床领域的应用得到扩展。用于研究炎症和神经退行性过程的新放射性配体正在开发中。在这里,我们讨论了 PET 成像在评估和监测各种疾病(包括骨关节炎、间质性肺病、血管血栓形成和骨质疏松症)方面的不断发展的潜在作用。